Nima Farzan, Kinnate Biopharma CEO
February 22, 2023 06:56 AM ESTUpdated February 23, 02:50 AM
Deals
China

Kin­nate en­gi­neers $24M deal to win con­trol of Chi­na joint ven­ture back from Or­biMed, Fore­site

Amber Tong

When Kin­nate Bio­phar­ma teamed up with Or­biMed and Fore­site to launch a joint ven­ture to bring its ki­nase in­hibitors to the Chi­nese mar­ket in 2021 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

A service from the Financial Times